Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites

被引：0
|
作者：
Buckland, R. J. [1 ]
Judge, H. M. [1 ]
Sugidachi, A. [2 ]
Jakubowski, J. A. [3 ]
Storey, R. F. [1 ]
机构：
[1] Univ Sheffield, Sch Med, Cardiovasc Res Unit, Sheffield, S Yorkshire, England
[2] Daiichi Sankyo Co Ltd, Biol Res Labs 2, Tokyo, Japan
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-TH-030
引用
收藏
页码：942 / 942
页数：1
相关论文
共 50 条
  • [41] The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts
    Savi, Pierre
    Zachayus, Jean-Luc
    Delesque-Touchard, Nathalie
    Labouret, Catherine
    Herve, Caroline
    Uzabiaga, Marie-Francoise
    Pereillo, Jean-Marie
    Culouscou, Jean-Michel
    Bono, Francoise
    Ferrara, Pascual
    Herbert, Jean-Marc
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (29) : 11069 - 11074
  • [42] The clopidogrel active metabolite disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts
    Savi, P
    Zachayus, JL
    Delesque-Touchard, N
    LabouretT, C
    Herve, C
    Uzabiaga, MF
    Pereillo, JM
    Culouscou, JM
    Bono, F
    Ferrara, P
    Herbert, JM
    FEBS JOURNAL, 2005, 272 : 228 - 228
  • [43] Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock
    Kanic, Vojko
    Kompara, Gregor
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 10
  • [44] The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Jakubowski, Joseph A.
    Payne, Christopher D.
    Li, Ying G.
    Brandt, John T.
    Small, David S.
    Farid, Nagy A.
    Salazar, Daniel E.
    Winters, Kenneth J.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 409 - 415
  • [45] Greater P2Y12 inhibition with prasugrel compared with clopidogrel in aspirin-treated patients based on higher plasma concentration of the active metabolite
    Varenhorst, Christoph
    Braun, Oscar
    James, Stefan
    Erlinge, David
    Winters, Kenneth J.
    Small, David S.
    Jakubowski, Joe T.
    Sugidachi, Atsuhiro
    Olofsson, Sylvia
    Siegbahn, Agneta
    Wallentin, Lars C.
    CIRCULATION, 2007, 116 (16) : 719 - 720
  • [46] Genetic variation in CYP2C19 affects exposure to the active metabolite and P2Y12 inhibition for clopidogrel but not prasugrel in patients with atherosclerosis
    Varenhorst, C.
    James, S.
    Erlinge, D.
    Braun, O. O.
    Winters, K. J.
    Man, M.
    Siegbahn, A.
    Walker, J.
    Wallentin, L.
    Close, S. L.
    EUROPEAN HEART JOURNAL, 2008, 29 : 327 - 327
  • [47] Importance of potent P2Y12 receptor blockade in acute myocardial infarction: focus on prasugrel
    Jeong, Young-Hoon
    Tantry, Udaya S.
    Gurbel, Paul A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (12) : 1771 - 1796
  • [48] Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
    William L. Baker
    C. Michael White
    American Journal of Cardiovascular Drugs, 2009, 9 : 213 - 229
  • [49] Effects of prasugrel (CS-747, LY640315) on platelet aggregation in P2Y12 receptor-deficient mice: Evidence for specific inhibition of P2Y12 receptors by prasugrel
    Sugidachi, A.
    Hashimoto, M.
    Ogawa, T.
    Isobe, T.
    Niitsu, Y.
    Jakubowski, J. A.
    Asai, F.
    EUROPEAN HEART JOURNAL, 2006, 27 : 758 - 759
  • [50] Functional variability of platelet response to clopidogrel correlates with P2Y12 receptor occupancy
    Sollier, Claire Bal Dit
    Berge, Natacha
    Boval, Bernadette
    Hovsepian, Lionel
    Drouet, Ludovic
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (01) : 116 - 122
12345